查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1941780

脑膜炎双球菌疫苗市场规模、份额和趋势分析报告：按类型、品牌、血清型、年龄层、销售管道、地区和细分市场预测，2026-2033年

Meningococcal Vaccines Market Size, Share & Trends Analysis Report By Type, By Brand, By Serotype, By Age Group (Infants ), By Sales Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

脑膜炎双球菌疫苗市场概述

2025年全球脑膜炎双球菌疫苗市场规模估计为40.5亿美元，预计2033年将达到59.6亿美元。

预计2026年至2033年，该市场将以4.5%的复合年增长率成长。脑膜炎发病率的上升预计将是推动市场成长的主要因素之一。

根据美国疾病管制与预防中心（CDC）预测，全球每年约有120万例细菌性脑膜炎病例。此外，疫苗接种计划的扩大、公众对该疾病的认识以及脑膜炎球菌疫苗研发活动的增加，预计将在预测期内推动市场成长。

脑膜炎双球菌疫苗是预防侵袭性脑膜炎双球菌病菌感染的重要手段，此病可导致危及生命的脑膜炎和败血症。这些疫苗有多种配方，包括四价疫苗（MenACWY）、B群疫苗（MenB）和五价疫苗（MenABCWY），分别针对引起疾病的主要血清群（A、B、C、W和Y）。截至2025年，监管机构已扩大核准，涵盖所有年龄组，MenQuadfi疫苗已获准用于预防6週龄及以上人群感染A、C、W和Y群脑膜炎球菌。公共卫生部门的常规疫苗接种建议持续强调青少年接种疫苗的重要性，并将其作为疾病控制的基础。例如，2025年7月，美国疾病管制与预防中心（CDC）的指引重申了青少年和高风险族群常规接种疫苗的重要性。

2024年至2025年的市场和监管趋势反映出一种策略转变，即转向使用能够简化免疫接种程序并提高覆盖率的广谱保护性疫苗。五价疫苗，例如辉瑞的Pembria和葛兰素史克的PenMemB（两者均覆盖A、B、C、W和Y群脑膜炎球菌），已核准用于10至25岁的人群，并结合了以往需要多种疫苗才能提供的保护。 2025年4月，美国免疫实务咨询委员会（ACIP）建议，当在同一次临床就诊中同时需要接种MenACWY和MenB疫苗时，应使用五价疫苗，从而简化接种通讯协定。例如，2025年4月，一个联邦咨询委员会建议使用五价脑膜炎双球菌疫苗，以支持更广泛、更全面的疫苗接种策略。

公共卫生指导和疫苗接种工作仍然专注于在广泛保护和有针对性的、基于风险的策略之间取得平衡。 2024年，美国食品药物管理局（FDA）更新了包括Bexsero在内的B群脑膜炎球菌疫苗的接种方案，以优化建议族群的免疫抗原性，这显示不断更新的证据和接种方案的持续改进。同时，在低收入地区进行的工作，例如2024年在非洲部分地区引入世界卫生组织建议的五价疫苗，显示全球需要将脑膜炎双球菌预防范围扩大到高所得市场以外的地区。疫苗可近性和政策的持续改进旨在透过适龄免疫接种来减轻全球病菌感染疾病的负担。

目录

第一章调查方法和范围

第二章执行摘要

3. 脑膜炎双球菌疫苗市场变数、趋势和范围

  • 市场体系展望
  • 市场动态
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析

第四章 脑膜炎双球菌疫苗市场：按类型分類的业务分析

  • 按类型分類的市场份额（2025 年和 2033 年）
  • 市场规模、预测与趋势分析：按类型划分（2021-2033 年）
  • 二价
  • 四价
  • 其他的

5. 脑膜炎双球菌疫苗市场：按品牌分類的业务分析

  • 按品牌分類的市场占有率（2025 年和 2033 年）
  • 市场规模、预测与趋势分析：按品牌划分（2021-2033 年）
  • Menactra
  • Menveo
  • Nimenrix
  • Trumenba
  • Bexsero

6. 脑膜炎双球菌疫苗市场：依血清型分類的业务分析

  • 以血清型分類的市场份额（2025 年和 2033 年）
  • 市场规模、预测与趋势分析：依血清型划分（2021-2033 年）
  • A
  • B
  • C
  • W-135
  • Y

7. 脑膜炎双球菌疫苗市场：按年龄组别分類的业务分析

  • 按年龄组别分類的市场份额（2025 年和 2033 年）
  • 市场规模、预测与趋势分析：按年龄组别划分（2021-2033 年）
  • 婴儿（0-2岁）
  • 儿童及成人（2岁以上）

8. 脑膜炎双球菌疫苗市场：按销售管道的业务分析

  • 按销售管道分類的市场份额（2025 年和 2033 年）
  • 按销售管道分類的市场规模、预测和趋势分析（2021-2033 年）
  • 私人的
  • 民众

第九章 脑膜炎双球菌疫苗市场：区域估算与趋势分析

  • 区域市场占有率分析（2025 年和 2033 年）
  • 区域市场概览
  • 市场规模及预测趋势分析（2021-2033）
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第十章 竞争格局

  • 参与公司概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/列表
    • GlaxoSmithKline
    • Pfizer
    • Sanofi
    • Merck &Co.
    • Novartis
    • Serum Institute of India
    • Walvax Biotechnology
    • Baxter International
    • Bio-Med Pvt. Ltd.
    • Incepta Vaccine Ltd
Product Code: GVR-4-68039-045-9

Meningococcal Vaccines Market Summary

The global meningococcal vaccines market size was estimated at USD 4.05 billion in 2025 and is projected to reach USD 5.96 billion by 2033, growing at a CAGR of 4.5% from 2026 to 2033. The increasing prevalence of meningitis is one of the major factors expected to drive the market.

According to the Centers for Disease Control and Prevention (CDC), approximately 1.2 million cases of bacterial meningitis are projected worldwide each year. Moreover, expanding immunization programs, greater awareness of the disease, and increased R&D activities for meningococcal vaccines are expected to fuel market growth during the forecast period.

Meningococcal vaccines are critical tools in preventing invasive Neisseria meningitidis infections, which can cause life-threatening meningitis and sepsis. These vaccines target the serogroups most responsible for disease-A, B, C, W, and Y-through distinct formulations, including quadrivalent (MenACWY), serogroup B (MenB), and pentavalent (MenABCWY). As of 2025, regulatory agencies have expanded approvals to improve coverage across age groups, with MenQuadfi licensed for individuals from six weeks of age to provide protection against serogroups A, C, W, and Y. Routine recommendations by public health authorities continue to emphasize adolescent immunization as foundational to disease control. For instance, in July 2025, CDC guidance reinforced the importance of routine vaccination for adolescents and at-risk individuals.

Market and regulatory developments in 2024-2025 reflect a strategic shift toward broader protective vaccines that simplify immunization schedules and enhance uptake. Pentavalent vaccines such as Pfizer's Penbraya and GSK's Penmenvy, each covering serogroups A, B, C, W, and Y, have received approval for use in individuals aged 10-25 years, consolidating protection previously provided by multiple vaccines. In April 2025, ACIP recommended using pentavalent vaccines when both MenACWY and MenB immunizations are indicated during the same clinical visit, streamlining delivery protocols. For instance, in April 2025, a federal advisory committee recommended pentavalent meningococcal vaccines to support broader, integrated vaccination approaches.

Public health guidance and vaccine uptake efforts remain focused on balancing broad protection with targeted risk-based strategies. In 2024, the FDA updated dosing schedules for MenB vaccines, such as Bexsero, to optimize immunogenicity in recommended cohorts, underscoring evolving evidence and refinements to dosing schedules. Concurrently, efforts in lower-income settings, such as the 2024 rollout of WHO-recommended five-strain vaccines in parts of Africa, illustrate the global imperative to extend meningococcal prevention beyond high-income markets. Continuing enhancements in vaccine access and policy aim to reduce the burden of meningococcal disease globally through age-appropriate immunization.

Global Meningococcal Vaccines Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends across sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global meningococcal vaccines market report based on type, brand, serotype, age group, sales channel, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Bivalent
  • Quadrivalent
  • Others
  • Brand Outlook (Revenue, USD Million, 2021 - 2033)
  • Menactra
  • Menveo
  • Nimenrix
  • Trumenba
  • Bexsero
  • Others
  • Serotype Outlook (Revenue, USD Million, 2021 - 2033)
  • A
  • B
  • C
  • W-135
  • Y
  • Age Group Outlook (Revenue, USD Million, 2021 - 2033)
  • Infants (0 to 2 years)
  • Children and Adults (2 years and above)
  • Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Private
  • Public
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Brand
    • 1.2.3. Serotype
    • 1.2.4. Age Group
    • 1.2.5. Sales Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Meningococcal Vaccines Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Meningococcal Vaccines Market: Type Business Analysis

  • 4.1. Type Market Share, 2025 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Bivalent
    • 4.4.1. Bivalent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Quadrivalent
    • 4.5.1. Quadrivalent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Meningococcal Vaccines Market: Brand Business Analysis

  • 5.1. Brand Market Share, 2025 & 2033
  • 5.2. Brand Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Brand, 2021 to 2033 (USD Million)
  • 5.4. Menactra
    • 5.4.1. Menactra Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Menveo
    • 5.5.1. Menveo Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Nimenrix
    • 5.6.1. Nimenrix Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Trumenba
    • 5.7.1. Trumenba Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Bexsero
    • 5.8.1. Bexsero Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Meningococcal Vaccines Market: Serotype Business Analysis

  • 6.1. Serotype Market Share, 2025 & 2033
  • 6.2. Serotype Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Serotype, 2021 to 2033 (USD Million)
  • 6.4. A
    • 6.4.1. A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. B
    • 6.5.1. B Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. C
    • 6.6.1. C Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. W-135
    • 6.7.1. W-135 Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Y
    • 6.8.1. Y Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Meningococcal Vaccines Market: Age Group Business Analysis

  • 7.1. Age Group Market Share, 2025 & 2033
  • 7.2. Age Group Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Age Group, 2021 to 2033 (USD Million)
  • 7.4. Infants (0 to 2 years)
    • 7.4.1. Infants (0 to 2 years) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Children and Adults (2 years and above)
    • 7.5.1. Children and Adults (2 years and above) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Meningococcal Vaccines Market: Sales Channel Business Analysis

  • 8.1. Sales Channel Market Share, 2025 & 2033
  • 8.2. Sales Channel Segment Dashboard
  • 8.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2021 to 2033 (USD Million)
  • 8.4. Private
    • 8.4.1. Private Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Public
    • 8.5.1. Public Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Meningococcal Vaccines Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Share Analysis, 2025 & 2033
  • 9.2. Regional Market Dashboard
  • 9.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 9.4. North America
    • 9.4.1. North America Meningococcal Vaccines Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 9.4.2. U.S.
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Type Disease Prevalence
      • 9.4.2.3. Regulatory Framework
      • 9.4.2.4. Reimbursement Framework
      • 9.4.2.5. U.S. Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.3. Canada
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Type Disease Prevalence
      • 9.4.3.3. Regulatory Framework
      • 9.4.3.4. Reimbursement Framework
      • 9.4.3.5. Canada Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.4. Mexico
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Type Disease Prevalence
      • 9.4.4.3. Regulatory Framework
      • 9.4.4.4. Reimbursement Framework
      • 9.4.4.5. Mexico Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. Europe
    • 9.5.1. Europe Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.2. UK
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Type Disease Prevalence
      • 9.5.2.3. Regulatory Framework
      • 9.5.2.4. Reimbursement Framework
      • 9.5.2.5. UK Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.3. Germany
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Type Disease Prevalence
      • 9.5.3.3. Regulatory Framework
      • 9.5.3.4. Reimbursement Framework
      • 9.5.3.5. Germany Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.4. France
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Type Disease Prevalence
      • 9.5.4.3. Regulatory Framework
      • 9.5.4.4. Reimbursement Framework
      • 9.5.4.5. France Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.5. Italy
      • 9.5.5.1. Key Country Dynamics
      • 9.5.5.2. Type Disease Prevalence
      • 9.5.5.3. Regulatory Framework
      • 9.5.5.4. Reimbursement Framework
      • 9.5.5.5. Italy Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.6. Spain
      • 9.5.6.1. Key Country Dynamics
      • 9.5.6.2. Type Disease Prevalence
      • 9.5.6.3. Regulatory Framework
      • 9.5.6.4. Reimbursement Framework
      • 9.5.6.5. Spain Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.7. Denmark
      • 9.5.7.1. Key Country Dynamics
      • 9.5.7.2. Type Disease Prevalence
      • 9.5.7.3. Regulatory Framework
      • 9.5.7.4. Reimbursement Framework
      • 9.5.7.5. Denmark Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.8. Sweden
      • 9.5.8.1. Key Country Dynamics
      • 9.5.8.2. Type Disease Prevalence
      • 9.5.8.3. Regulatory Framework
      • 9.5.8.4. Reimbursement Framework
      • 9.5.8.5. Sweden Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.9. Norway
      • 9.5.9.1. Key Country Dynamics
      • 9.5.9.2. Type Disease Prevalence
      • 9.5.9.3. Regulatory Framework
      • 9.5.9.4. Reimbursement Framework
      • 9.5.9.5. Norway Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Asia Pacific
    • 9.6.1. Asia Pacific Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.2. Japan
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Type Disease Prevalence
      • 9.6.2.3. Regulatory Framework
      • 9.6.2.4. Reimbursement Framework
      • 9.6.2.5. Japan Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.3. China
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Type Disease Prevalence
      • 9.6.3.3. Regulatory Framework
      • 9.6.3.4. Reimbursement Framework
      • 9.6.3.5. China Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.4. India
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Type Disease Prevalence
      • 9.6.4.3. Regulatory Framework
      • 9.6.4.4. Reimbursement Framework
      • 9.6.4.5. India Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.5. Australia
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Type Disease Prevalence
      • 9.6.5.3. Regulatory Framework
      • 9.6.5.4. Reimbursement Framework
      • 9.6.5.5. Australia Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.6. South Korea
      • 9.6.6.1. Key Country Dynamics
      • 9.6.6.2. Type Disease Prevalence
      • 9.6.6.3. Regulatory Framework
      • 9.6.6.4. Reimbursement Framework
      • 9.6.6.5. South Korea Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.7. Thailand
      • 9.6.7.1. Key Country Dynamics
      • 9.6.7.2. Type Disease Prevalence
      • 9.6.7.3. Regulatory Framework
      • 9.6.7.4. Reimbursement Framework
      • 9.6.7.5. Thailand Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7. Latin America
    • 9.7.1. Latin America Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.7.2. Brazil
      • 9.7.2.1. Key Country Dynamics
      • 9.7.2.2. Type Disease Prevalence
      • 9.7.2.3. Regulatory Framework
      • 9.7.2.4. Reimbursement Framework
      • 9.7.2.5. Brazil Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.7.3. Argentina
      • 9.7.3.1. Key Country Dynamics
      • 9.7.3.2. Type Disease Prevalence
      • 9.7.3.3. Regulatory Framework
      • 9.7.3.4. Reimbursement Framework
      • 9.7.3.5. Argentina Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8. Middle East and Africa
    • 9.8.1. Middle East and Africa Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.2. South Africa
      • 9.8.2.1. Key Country Dynamics
      • 9.8.2.2. Type Disease Prevalence
      • 9.8.2.3. Regulatory Framework
      • 9.8.2.4. Reimbursement Framework
      • 9.8.2.5. South Africa Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.3. Saudi Arabia
      • 9.8.3.1. Key Country Dynamics
      • 9.8.3.2. Type Disease Prevalence
      • 9.8.3.3. Regulatory Framework
      • 9.8.3.4. Reimbursement Framework
      • 9.8.3.5. Saudi Arabia Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.4. UAE
      • 9.8.4.1. Key Country Dynamics
      • 9.8.4.2. Type Disease Prevalence
      • 9.8.4.3. Regulatory Framework
      • 9.8.4.4. Reimbursement Framework
      • 9.8.4.5. UAE Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.5. Kuwait
      • 9.8.5.1. Key Country Dynamics
      • 9.8.5.2. Type Disease Prevalence
      • 9.8.5.3. Regulatory Framework
      • 9.8.5.4. Reimbursement Framework
      • 9.8.5.5. Kuwait Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Participant Overview
  • 10.2. Company Market Position Analysis
  • 10.3. Company Categorization
  • 10.4. Strategy Mapping
  • 10.5. Company Profiles/Listing
    • 10.5.1. GlaxoSmithKline
      • 10.5.1.1. Overview
      • 10.5.1.2. Financial Performance
      • 10.5.1.3. Type Benchmarking
      • 10.5.1.4. Strategic Initiatives
    • 10.5.2. Pfizer
      • 10.5.2.1. Overview
      • 10.5.2.2. Financial Performance
      • 10.5.2.3. Type Benchmarking
      • 10.5.2.4. Strategic Initiatives
    • 10.5.3. Sanofi
      • 10.5.3.1. Overview
      • 10.5.3.2. Financial Performance
      • 10.5.3.3. Type Benchmarking
      • 10.5.3.4. Strategic Initiatives
    • 10.5.4. Merck & Co.
      • 10.5.4.1. Overview
      • 10.5.4.2. Financial Performance
      • 10.5.4.3. Type Benchmarking
      • 10.5.4.4. Strategic Initiatives
    • 10.5.5. Novartis
      • 10.5.5.1. Overview
      • 10.5.5.2. Financial Performance
      • 10.5.5.3. Type Benchmarking
      • 10.5.5.4. Strategic Initiatives
    • 10.5.6. Serum Institute of India
      • 10.5.6.1. Overview
      • 10.5.6.2. Financial Performance
      • 10.5.6.3. Type Benchmarking
      • 10.5.6.4. Strategic Initiatives
    • 10.5.7. Walvax Biotechnology
      • 10.5.7.1. Overview
      • 10.5.7.2. Financial Performance
      • 10.5.7.3. Type Benchmarking
      • 10.5.7.4. Strategic Initiatives
    • 10.5.8. Baxter International
      • 10.5.8.1. Overview
      • 10.5.8.2. Financial Performance
      • 10.5.8.3. Type Benchmarking
      • 10.5.8.4. Strategic Initiatives
    • 10.5.9. Bio-Med Pvt. Ltd.
      • 10.5.9.1. Overview
      • 10.5.9.2. Financial Performance
      • 10.5.9.3. Type Benchmarking
      • 10.5.9.4. Strategic Initiatives
    • 10.5.10. Incepta Vaccine Ltd
      • 10.5.10.1. Overview
      • 10.5.10.2. Financial Performance
      • 10.5.10.3. Type Benchmarking
      • 10.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Meningococcal Vaccines Market, by Region, 2021 - 2033 (USD Million)
  • Table 4 Global Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 5 Global Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 6 Global Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 7 Global Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 8 Global Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 9 North America Meningococcal Vaccines Market, by Country, 2021 - 2033 (USD Million)
  • Table 10 North America Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 11 North America Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 12 North America Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 13 North America Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 14 North America Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 15 U.S Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 16 U.S Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 17 U.S Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 18 U.S Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 19 U.S Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 20 Canada Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 21 Canada Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 22 Canada Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 23 Canada Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 24 Canada Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 25 Mexico Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 26 Mexico Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 27 Mexico Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 28 Mexico Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 29 Mexico Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 30 Europe Meningococcal Vaccines Market, by Country, 2021 - 2033 (USD Million)
  • Table 31 Europe Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 32 Europe Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 33 Europe Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 34 Europe Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 35 Europe Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 36 UK Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 37 UK Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 38 UK Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 39 UK Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 40 UK Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 41 Germany Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 42 Germany Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 43 Germany Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 44 Germany Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 45 Germany Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 46 France Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 47 France Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 48 France Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 49 France Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 50 France Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 51 Italy Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 52 Italy Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 53 Italy Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 54 Italy Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 55 Italy Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 56 Spain Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 57 Spain Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 58 Spain Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 59 Spain Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 60 Spain Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 61 Denmark Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 62 Denmark Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 63 Denmark Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 64 Denmark Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 65 Denmark Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 66 Norway Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 67 Norway Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 68 Norway Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 69 Norway Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 70 Norway Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 71 Sweden Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 72 Sweden Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 73 Sweden Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 74 Sweden Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 75 Sweden Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 76 Asia Pacific Meningococcal Vaccines Market, by Country, 2021 - 2033 (USD Million)
  • Table 77 Asia Pacific Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 78 Asia Pacific Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 79 Asia Pacific Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 80 Asia Pacific Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 81 Asia Pacific Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 82 Japan Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 83 Japan Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 84 Japan Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 85 Japan Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 86 Japan Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 87 China Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 88 China Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 89 China Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 90 China Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 91 China Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 92 India Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 93 India Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 94 India Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 95 India Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 96 India Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 97 South Korea Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 98 South Korea Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 99 South Korea Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 100 South Korea Meningococcal Vaccines Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 101 South Korea Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 102 Australia Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 103 Australia Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 104 Australia Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 105 Australia Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 106 Australia Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 107 Thailand Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 108 Thailand Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 109 Thailand Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 110 Thailand Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 111 Thailand Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 112 Latin America Meningococcal Vaccines Market, by Country, 2021 - 2033 (USD Million)
  • Table 113 Latin America Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 114 Latin America Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 115 Latin America Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 116 Latin America Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 117 Latin America Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 118 Brazil Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 119 Brazil Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 120 Brazil Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 121 Brazil Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 122 Brazil Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 123 Argentina Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 124 Argentina Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 125 Argentina Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 126 Argentina Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 127 Argentina Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 128 Middle East & Africa Meningococcal Vaccines Market, by Country, 2021 - 2033 (USD Million)
  • Table 129 Middle East & Africa Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 130 Middle East & Africa Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 131 Middle East & Africa Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 132 Middle East & Africa Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 133 Middle East & Africa Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 134 South Africa Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 135 South Africa Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 136 South Africa Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 137 South Africa Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 138 South Africa Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 139 Saudi Arabia Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 140 Saudi Arabia Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 141 Saudi Arabia Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 142 Saudi Arabia Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 143 Saudi Arabia Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 144 UAE Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 145 UAE Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 146 UAE Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 147 UAE Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 148 UAE Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 149 Kuwait Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 150 Kuwait Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 151 Kuwait Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 152 Kuwait Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 153 Kuwait Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Meningococcal Vaccines market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and disease outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Meningococcal Vaccines market dynamics
  • Fig. 12 Meningococcal Vaccines market: Porter's five forces analysis
  • Fig. 13 Meningococcal Vaccines market: PESTLE analysis
  • Fig. 14 Type market, 2021 - 2033 (USD Million)
  • Fig. 15 Bivalent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 16 Quadrivalent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 17 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 Brand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 Menactra market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 Menveo market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 Nimenrix market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Trumenba market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Bexsero market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Serotype market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 A market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 B market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 C market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 W-135 Molecule market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Y market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Age Group market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Infants (0 to 2 years) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Children and Adults (2 years and above) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Sales Channel market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Private market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Public market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Meningococcal Vaccines market revenue, by region
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 North America meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 U.S country dynamics
  • Fig. 41 U.S meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Canada country dynamics
  • Fig. 43 Canada meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Mexico country dynamics
  • Fig. 45 Mexico meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Europe meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 UK country dynamics
  • Fig. 48 UK meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Germany country dynamics
  • Fig. 50 Germany meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 France country dynamics
  • Fig. 52 France meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Italy country dynamics
  • Fig. 54 Italy meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Spain country dynamics
  • Fig. 56 Spain meningococcal vaccines market, 2021 - 2033 (USD Million)
  • Fig. 57 Norway country dynamics
  • Fig. 58 Norway meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Sweden country dynamics
  • Fig. 60 Sweden meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Denmark country dynamics
  • Fig. 62 Denmark meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Asia Pacific meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Japan country dynamics
  • Fig. 65 Japan meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 China country dynamics
  • Fig. 67 China meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 India country dynamics
  • Fig. 69 India meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Australia country dynamics
  • Fig. 71 Australia meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 South Korea country dynamics
  • Fig. 73 South Korea meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Thailand country dynamics
  • Fig. 75 Thailand meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Latin America meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Brazil country dynamics
  • Fig. 78 Brazil meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 Argentina country dynamics
  • Fig. 80 Argentina meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 MEA meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 South Africa country dynamics
  • Fig. 83 South Africa meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Saudi Arabia country dynamics
  • Fig. 85 Saudi Arabia meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 UAE country dynamics
  • Fig. 87 UAE meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Kuwait country dynamics
  • Fig. 89 Kuwait meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Company categorization
  • Fig. 91 Company market position analysis
  • Fig. 92 Strategic framework